Nektar Therapeutics NKTR
Set alert
As of Nov 2, 3:07 PM ET
- YTD
- -11.41%
- 1 year
- -42.31%
- Open
- 38.65
- Prev close
- 38.87
- Mkt cap
- 1.28B
- Vol
- 396.53K
- Avg vol
- 1.10M
- EPS
- -18.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 37.26
- High
- 39.01
- Forward P/E
- -3.77
- Beta
- 1.27
- Short ratio
- 3.62
- Inst. own
- 107.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 56.40
- 200-d avg
- 64.99
- 1y target
- 133.08
News
3 days ago seekingalpha.com
Nektar Therapeutics: Focus Returns To The Strengths Of The Company
NKTR's rezpegaldesleukin is now in phase 3 trials in atopic dermatitis, but there is additional data from the company's phase 2b REZOLVE-AD trial expected in Q1'27. The market focus has shifting back…
4 days ago zacks.com
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago prnewswire.com
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026,…
1 week ago prnewswire.com
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors…
2 weeks ago defenseworld.net
Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial Analysis
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) and Maze Therapeutics (NASDAQ: MAZE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
2 weeks ago zacks.com
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.
-
3 weeks ago benzinga.com
UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.
-
3 weeks ago benzinga.com
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
-
3 weeks ago benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
-
3 weeks ago benzinga.com
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating
Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.
3 weeks ago seekingalpha.com
Cedar Grove Capital Q3 2026 Portfolio Update
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican…
1 month ago defenseworld.net
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Down – Here’s What Happened
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price gapped down prior to trading on Thursday. The stock had previously closed at $60.54, but opened at $55.41. Nektar Therapeutics…
1 month ago seekingalpha.com
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More
Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7%…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock…
1 month ago seekingalpha.com
Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript
Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript
1 month ago marketbeat.com
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
Nektar Therapeutics NASDAQ: NKTR presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to…
1 month ago barrons.com
Nektar Stock Sinks Despite Promising Hair Loss Treatment Data
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.
1 month ago schaeffersresearch.com
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make…
-
1 month ago benzinga.com
Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of…
1 month ago prnewswire.com
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg…
1 month ago defenseworld.net
Nektar Therapeutics (NASDAQ:NKTR) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen ratings firms that are covering the company, Marketbeat reports. One…
1 month ago gurufocus.com
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple I
1 month ago prnewswire.com
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ --…
1 month ago prnewswire.com
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata Company to host conference call with investors…
-
1 month ago benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
1 month ago prnewswire.com
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of…
1 month ago benzinga.com
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.
-
1 month ago benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
-
1 month ago benzinga.com
Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million…
-
1 month ago benzinga.com
Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.
1 month ago defenseworld.net
Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
-
1 month ago benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
-
1 month ago benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
-
2 months ago benzinga.com
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support…
-
2 months ago benzinga.com
JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.
2 months ago benzinga.com
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call
Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…
-
3 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153
Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.
3 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 months ago benzinga.com
Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029
Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with…
-
5 months ago benzinga.com
Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $95 to $80.
-
5 months ago benzinga.com
Nektar Therapeutics To Offer Up To $150M In Common Stock Via Equity Distribution Agreement
On May 8, 2026, Nektar Therapeutics (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and H.C. Wainwright &…
-
5 months ago benzinga.com
Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192
Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.
-
5 months ago benzinga.com
Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses…
-
6 months ago benzinga.com
Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151
Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $123 to $151.
-
6 months ago benzinga.com
Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.
-
6 months ago benzinga.com
Nektar Therapeutics Launches $250M Common Stock Offering
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an…
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $185
HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $165 to $185.
-
6 months ago benzinga.com
BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $178
BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $151 to $178.
6 months ago benzinga.com
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.